-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 13, 2021, Veru announced that the US FDA has approved Entadfi for the treatment of urinary tract symptoms caused by benign prostatic hyperplasia (BPH)
BPH is a common disease in middle-aged and elderly men and one of the main causes of lower urinary tract symptoms.
▲The curative effect result of finasteride and tadalafil in combination (picture source: Veru official website)
Veru's Entadfi is a unique compound formula that meets the FDA's bioavailability and bioequivalence standards compared with taking finasteride and tadalafil at the same time
Reference materials:
[1] Veru Announces FDA Approval of Entadfi, a New Treatment for Benign Prostatic Hyperplasia.
(The original text has been deleted)